Literature DB >> 30975568

Influenza in Latin America: A report from the Global Influenza Initiative (GII).

Angela Gentile1, John Paget2, Nancy Bellei3, Juan Pablo Torres4, Cynthia Vazquez5, V Alberto Laguna-Torres6, Stanley Plotkin7.   

Abstract

The Global Influenza Initiative (GII) is a global expert group that aims to raise acceptance and uptake of influenza vaccines globally and provides recommendations and strategies to address challenges at local, national, regional, and global levels. This article provides a consolidated estimation of disease burden in Latin America, currently lacking in published literature, and delivers the GII recommendations specific to Latin America that provide guidance to combat existing vaccination challenges. While many countries worldwide, especially in the tropics and subtropics, do not have a seasonal influenza policy, 90% of Latin American countries have a seasonal influenza policy in place. Local governments in the Latin American countries and The Pan American Health Organization's Technical Advisory Group on Vaccine-preventable Diseases play a major role in improving the vaccination coverage and reducing the overall disease burden. Influenza seasonality poses the biggest challenge in deciding on optimal timing for vaccination in Latin America, as in temperate climates seasonal influenza activity peaks during the winter months (November-February and May-October) in the northern and southern hemispheres, respectively, while in the tropics and subtropical regions it usually occurs throughout the year, but especially during the rainy season. Besides this, vaccine mismatch with circulating strains, misconception concerning influenza vaccine effectiveness, and poor disease and vaccine awareness among the public are also key challenges that need to be overcome. Standardization of clinical case definitions is important across all Latin American countries. Surveillance (mostly passive) has improved substantially in the Latin American countries over the past decade, but more is still required to better understand the disease burden and help inform policies.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Keywords:  Epidemiology; Global Influenza Initiative; Influenza; Latin America; Surveillance; Vaccination

Year:  2019        PMID: 30975568     DOI: 10.1016/j.vaccine.2019.03.081

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Influenza vaccine effectiveness among outpatients in the US Influenza Vaccine Effectiveness Network by study site 2011-2016.

Authors:  Goundappa K Balasubramani; Mary Patricia Nowalk; Theresa M Sax; Joe Suyama; Emily Bobyock; Charles R Rinaldo; Emily T Martin; Arnold S Monto; Michael L Jackson; Manjusha J Gaglani; Brendan Flannery; Jessie R Chung; Richard K Zimmerman
Journal:  Influenza Other Respir Viruses       Date:  2020-04-16       Impact factor: 5.606

2.  FluA-p score: a novel prediction rule for mortality in influenza A-related pneumonia patients.

Authors:  Liang Chen; Xiudi Han; Yan Li Li; Chunxiao Zhang; Xiqian Xing
Journal:  Respir Res       Date:  2020-05-08

3.  YouTube as a Source of Influenza Vaccine Information in Spanish.

Authors:  Ignacio Hernández-García; Teresa Giménez-Júlvez
Journal:  Int J Environ Res Public Health       Date:  2021-01-15       Impact factor: 3.390

4.  Should the Holy Week 2020 be cancelled in Latin America due to the COVID-19 pandemic?

Authors:  Alfonso J Rodriguez-Morales; Ranjit Sah; Alberto Paniz-Mondolfi
Journal:  Travel Med Infect Dis       Date:  2020-03-20       Impact factor: 6.211

5.  Influenza vaccination hesitancy in large urban centers in South America. Qualitative analysis of confidence, complacency and convenience across risk groups.

Authors:  Miguel Ángel González-Block; Blanca Estela Pelcastre-Villafuerte; Daniela Riva Knauth; Andréa Fachel-Leal; Yamila Comes; Pedro Crocco; Laura Noboa; Berenice Rodríguez Zea; Mónica Ruoti; Sandra Patricia Díaz Portillo; Elsa Sarti
Journal:  PLoS One       Date:  2021-08-12       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.